2015
DOI: 10.1016/j.molimm.2015.01.028
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Complement is recognized as a key player in a wide range of normal as well as disease-related immune, developmental and homeostatic processes. Knowledge of complement components, structures, interactions, and cross-talk with other biological systems continues to grow and this leads to novel treatments for cancer, infectious, autoimmune- or age-related diseases as well as for preventing transplantation rejection. Antibodies are superbly suited to be developed into therapeutics with appropriate complement stimul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
54
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 112 publications
(54 citation statements)
references
References 197 publications
(197 reference statements)
0
54
0
Order By: Relevance
“…However, efforts are still needed to improve its thermostability, solubility, and its binding affinity to C1q and CDC activity before it can really compete with its glycosylated peer for cancer therapy. On the other hand, the inability of aglycosylated mAbs to bind to C1q may have beneficial effects when CDC activity is not required such as for treatment of autoimmune diseases where CDC is chronically and pathologically activated (102). Similarly, aglycosylated mAbs may have advantages over glycosylated counterparts when only selective activation of FcγRs is desired such as activation of FcγRI (63) or FcγRIIa (84) to stimulate tumor cell killing.…”
Section: Final Remarksmentioning
confidence: 99%
“…However, efforts are still needed to improve its thermostability, solubility, and its binding affinity to C1q and CDC activity before it can really compete with its glycosylated peer for cancer therapy. On the other hand, the inability of aglycosylated mAbs to bind to C1q may have beneficial effects when CDC activity is not required such as for treatment of autoimmune diseases where CDC is chronically and pathologically activated (102). Similarly, aglycosylated mAbs may have advantages over glycosylated counterparts when only selective activation of FcγRs is desired such as activation of FcγRI (63) or FcγRIIa (84) to stimulate tumor cell killing.…”
Section: Final Remarksmentioning
confidence: 99%
“…A nti-tumor mAbs that are used in the immunotherapy of cancer can promote destruction of cancer cells by several mechanisms (1)(2)(3)(4)(5). It is now well-recognized that amino acid or carbohydrate changes engineered into the Ab Fc regions can substantially enhance their cytotoxic action because of increased and more effective use of immune-based effector functions (2,(6)(7)(8)(9)(10)(11).…”
mentioning
confidence: 99%
“…12,34,51,52 It is thought to have a role in a wide variety of diseases such as pathogenesis of psoriasis, adult respiratory distress syndrome, bullous pemphigoid, rheumatoid arthritis, ischemia-reperfusion injury, glomerulopathy, systemic lupus erythematosus and in trauma where presence of anaphylatoxins significantly increases risk of mortality rate. [53][54][55][56][57][58] Although a fundamental part of innate host defense, over activation (by release of the anaphylatoxins C3a and C5a (Fig. 1) as well as the membrane attack complex) can lead to host damage (vide supra) which results, for example, in worsening of prognosis for patients, as observed with septicemia.…”
Section: The Complement Systemmentioning
confidence: 99%